Orchestra BioMed Holdings (OBIO) Cash from Financing Activities (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Cash from Financing Activities for 5 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 1967.23% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $94.2 million (up 226.28% YoY), while the FY2025 annual figure was $88.3 million, up 202.81% from the prior year.
• Cash from Financing Activities declined to $5.5 million in Q1 2026 per OBIO's latest filing, from $12.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $86.1 million in Q2 2022 and bottomed at -$10.7 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $16.0 million across 5 years, with a median of $171000.0 in 2024.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 375775.0% — and 2025, when it plunged 1744.44%.
• Orchestra BioMed Holdings' Cash from Financing Activities stood at -$5.1 million in 2022, then tumbled by 110.14% to -$10.7 million in 2023, then surged by 230.39% to $13.9 million in 2024, then fell by 9.23% to $12.7 million in 2025, then sank by 56.34% to $5.5 million in 2026.
• Business Quant data shows OBIO's Cash from Financing Activities at $5.5 million in Q1 2026, $12.7 million in Q4 2025, and $76.4 million in Q3 2025.